Reading Time: 2 minutesIntroduction Hypogonadism, a condition characterized by the body's inability to produce sufficient testosterone, affects a significant number of American males. Delatestryl, a testosterone enanthate injection developed by Endo Pharmaceuticals, has been a cornerstone in the management of this condition. This article provides an extensive review of clinical data focusing on the long-term safety and tolerability of Delatestryl in American males with hypogonadism. Overview of Hypogonadism and Delatestryl Hypogonadism can lead to a variety of symptoms, including decreased libido, fatigue, and muscle loss. Delatestryl, administered via intramuscular injection, aims to restore testosterone levels to normal, thereby alleviating these symptoms. The drug's … Continue reading →